Model N acquired Kalderos, giving life sciences companies a more proactive and precise way to manage 340B across contracting, claims validation, and payment workflows.
With Model N, you are in command of every stage of commercialization – from gross-to-net, compliance, global price management, global market access, and beyond. Our technology, data, and expertise give you the visibility and control to ensure every price, incentive, and contract drives profit, not problems. Revenue is optimized. Compliance is assured. And every decision fuels innovation and scalable growth.
Accelerate digital transformation with cloud-integrated technology, data, analytics, and expert services, so you can respond with agility to market and regulatory changes while mitigating risk and growing your revenue.
Losing revenue stifles innovation. Model N’s purpose-built products and services empower innovators by optimizing revenue to grow your true top line – all while gaining actionable insights and process enhancements along the way.
Model N connects and automates end-to-end revenue processes – including gross to net – delivering deep insight and control to drive current and future growth.
Automating your government pricing compliance processes with Model N empowers you to achieve accuracy, reproducibility, and audibility – so you’re always compliant and audit-ready.
Model N empowers you to harness timely, accurate, and AI-ready data with actionable insights – enabling smarter, faster decisions that optimize revenue, ensure compliance, and embrace intelligent automation.
Automate commercialization processes from contract creation to rebate payment.
Deliver access to key data and insights directly to Salesforce.
Improve the profitability of commercial contracts with enhanced compliance.
See how companies like yours leverage Model N to enhance operations, boost growth and optimize resources to drive innovation.
of the world’s leading companies trust Model N
compliance with industry and government regulations
projected savings delivered across our life sciences customers
return on investment
